Does COVID-19 impact the prevalence of myositis specific antibodies in the Netherlands? A comparative nationwide study

•Study with nationwide data on MSAs (n=4962 samples) from a pre-COVID-19 year and a year within the pandemic.•Three MSAs (PL7, SRP and MDA5) are more prevalent during the COVID-19 pandemic as compared to before the pandemic.•The same three MSAs were previously reported by others in hospitalized pati...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of autoimmunity Vol. 139; p. 103081
Main Authors:	Kamperman, Renske G, van Leeuwen, Ester MM, Willems, Myrthe, van der Kooi, Anneke J, Gelderman, Kyra A, Hamann, Dörte, van Lochem, Ellen G, Meek, Bob, van der Molen, Renate G, Platteel, Anouk CM, Otten, Henny G, Schreurs, Marco WJ, Raaphorst, Joost
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01-09-2023
Subjects:	COVID-19 Myositis Myositis specific antibodies COVID-19 Myositis Myositis specific antibodies
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	•Study with nationwide data on MSAs (n=4962 samples) from a pre-COVID-19 year and a year within the pandemic.•Three MSAs (PL7, SRP and MDA5) are more prevalent during the COVID-19 pandemic as compared to before the pandemic.•The same three MSAs were previously reported by others in hospitalized patients with SARS-CoV-2.•Our findings substantiate auto-immunity triggered by SARS-CoV-2 on a population level.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0896-8411 1095-9157
DOI:	10.1016/j.jaut.2023.103081